vasopharm GmbH Announces Brain Glutamate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

/in

Ronopterin significantly reduces glutamate levels measured in brain microdialysate from TBI patients, an important and long sought indicator of biochemical neuroprotection Combined inhibition of nitric oxide synthesis and glutamate increase expands our understanding of Ronopterin’s mode of action and its association with improved outcome in TBI Decreasing glutamate adds to the previously reported reduction in […]

Read more

Novo Nordisk Foundation – Researchers mobilise to combat antimicrobial resistance

/in

Antibiotics are used to treat or prevent some types of bacterial infection, for example in the airways or digestive tract of humans and pigs. However, the current overuse of antibiotics leads to bacteria developing resistance and thus creating a lack of antibiotic efficacy and, worst case, a complete lack of therapeutic options to treat bacterial […]

Read more

ImaginAb Announces New Supply Agreement to Supply Genmab A/S with its Investigational CD8 ImmunoPET Agent

/in

Los Angeles, CA, USA, May 5th, 2022 – ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce it has signed a new multi-year, non-exclusive supply agreement with Genmab A/S, an international biotechnology company. Read more…

Read more

AMSilk appoints Klaus Kjedal as Chief Production Officer and Managing Director

/in

Munich, Germany, 04 May 2022 – AMSilk GmbH (“AMSilk”), a world leader in supplying innovative high-performance bio-based silk materials, today announces the appointment of Klaus Kjedal as Chief Production Officer (CPO) and Managing Director (MD). Read more…

Read more

Gadeta to Attend Upcoming Business and Investor Conferences

/in

Utrecht, Netherlands and Boston, Mass., 4th May 2022: Gadeta B.V. (‘Gadeta’), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for every cancer patient, today announces it will be attending the following conferences: Read more

Read more
© Optimum Strategic Communications.